After the tremendous success of imatinib therapy in BCR-ABL-positive chronic myelogenous leukemia, imatinib was tried in various myeloproliferative disorders and patients with eosinophilia were found to be particularly sensitive. The gene discussed is ABL1; the disease is myeloproliferative disorder.